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ABSTRACT 
Polo-like kinase 1 (Plk1) plays several roles in mitosis, and it has been suggested to 
have a role in tumorigenesis. We have previously reported that Plk1 depletion results in 
cell death in cancer cells, whereas normal cells survive similar depletion. However, 
Plk1 depletion together with p53 depletion induces cell death in normal cells as well. 
This communication presents evidence on the sequence of events that leads to cell death 
in cancer cells. DNA damage is detected at the first S phase following Plk1 depletion 
and is more severe in Plk1-depleted p53-null cancer cells. As a consequence of Plk1 
depletion using lentivirus-based siRNA techniques, pre-replicative complex (pre-RC) 
formation is disrupted at the G1/S transition and DNA synthesis is reduced during S 
phase of the first cycle after depletion. The levels of geminin, an inhibitor of DNA pre-
RC, and Emi1, an inhibitor of APC/C, are elevated in Plk1-depleted cells. The rate of 
cell cycling is slower in Plk1-depleted cells than in control cells when synchronized by 
serum starvation. Plk1 depletion results in disrupted DNA pre-RC, reduced DNA 
synthesis and DNA damage before cells display severe mitotic catastrophe or apoptosis. 
Our data suggest that Plk1 is required for cell cycle progression not only in mitosis but 
also for DNA synthesis, maintenance of DNA integrity and prevention of cell death.  
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INTRODUCTION 
 
Progression of the cell cycle is tightly regulated in eukaryotic cells by coordinated 
control of phosphorylation and proteolytic events. Duplication of genetic information 
for the next cell generation requires the precise coordination of numerous proteins (2). 
To ensure the accurate division of duplicated DNA, cells require condensed 
chromosomes, a mitotic spindle, and correct attachment of duplicated chromosomes to 
the spindle. Errors in DNA replication and mitosis may lead to cell death through 
apoptosis or result in mutations that lead to cancer (3). Polo-like kinase 1 (Plk1) is 
essential for several steps in mitosis, and is highly expressed in proliferating cells. 
Expression of Plk1 increases in S phase and peaks during M phase (8). In addition, at 
the G2/M boundary Plk1 is activated by phosphorylation and promotes mitotic entry. Its 
primary role in mammalian cells appears to be control of mitotic progression, 
particularly in the metaphase-anaphase transition, and mitotic exit (37). At the G2/M 
transition, Plx1, a counterpart of Plk1 in Xenopus, activates cyclin B1/Cdk1 by 
phosphorylation of Cdc25C (14), or of cyclin B1 (29). During mitotic entry, Plk1 is 
required for recruitment of the γ-tubulin ring complex (7). Phosphorylation of Emi1 by 
Plk1 leads to its destruction, release of Cdc20, and activation of the anaphase-promoting 
complex/cyclosome (APC/C) (10, 22, 26). Active APC/C mediates the degradation of 
proteins such as cyclin A, cyclin B1, securin, and geminin to promote exit from mitosis 
(6, 26). The multiple roles of Plk1 from the entry to and exit from mitosis indicate its 
importance as a regulator of these events. 
Recently several reports suggest that Plk1 may play a role in other phases of the cell 
cycle. Plk1 interacts with pre-replicative complex proteins, such as Mcm2 and Orc2, in 
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yeast two-hybrid studies (32), and coimmunoprecipitates with Mcm2-7 and Orc2 (32, 
35). Orc2, Mcm4, Mcm6 and Mcm7 proteins colocalize in the centrosome with Plk1 (25, 
32). In addition, ectopic expression of Plk1-S137D arrests HeLa cells at the G1/S 
boundary (12). Moreover, microinjection of in vitro transcribed sense mRNA of Plk1 
into serum-starved NIH 3T3 cells induced thymidine incorporation, whereas 
microinjection of antisense mRNA into growing NIH 3T3 cells that were stimulated 
with serum blocked thymidine incorporation (9). This observation suggests that Plk1 is 
required for DNA synthesis and that overexpression of Plk1 appears to be sufficient for 
induction of DNA synthesis. These data raise the possibility that Plk1 might have a 
required function in DNA replication.  
Depletion of Plk1 activity by microinjection of neutralizing anti-Plk1 antibody impairs 
centrosome maturation in HeLa cells (15). When Plk1 function is blocked by dominant-
negative Plk1, several human tumor cells undergo mitotic catastrophe independent of 
Cdc25C (1). In Plk1-deficient human cancer cells, centrosomes do not separate to form 
bipolar spindles. The cells undergo prometaphase arrest and cell death caused by mitotic 
catastrophe (18, 33, 38). These effects are more severe in p53-deficient cancer cells. 
Cells co-depleted for p53 and Plk1 undergo cell death as a consequence of mitotic 
defects (17). However, it is unclear how Plk1 depletion induces cell death or what the 
sequence of events is prior to cell death.  
Here, we provide evidence that Plk1 depletion induces DNA damage at G1/S before cell 
death responses such as caspase activation are initiated.  
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RESULTS 
 
The formation of γ-H2A.X foci precedes the activation of caspase-3 in Plk1-
depleted cancer cells.  
In previous studies, we reported that the Plk1-depleted cancer cells undergo apoptosis 
(17, 18). FACS analysis and activation of caspase-3 showed that Plk1 depletion induced 
severe apoptosis in puromycin-selected cells 3-5 days after infection of Plk1 targeting 
lentivirus (P) compared with control virus carrying the pLKO-puro.1 vector (C) in HeLa 
cells (Supplementary Fig. 1, A-B). Lentivirus-expressing mutant RNAi sequence target 
of Plk1 (M) was used for the off-target control. Histone H2A.X was phosphorylated and 
cleaved caspase-3 was detected at 3 days after Plk1 depletion whereas the ratio of γ-
H2A.X-positive cells or cleaved caspase-3-positive cells was low in vector control or 
off-target control (Supplementary Fig. 1, C- D), which suggests that DNA damage and 
apoptosis occurred in Plk1-depleted cancer cells. However, the sequence of events was 
unclear. 
To investigate this issue, lentivirus-infected cells were not selected by puromycin 
because the infection efficiency was very high and the treatment of puromycin could 
influence the DNA damage response and also cells were observed within 48 h after 
infection (Supplementary Fig. 2A). Because caspase-3 was activated at 24-48 h after 
release as measured by enzyme assay using caspase-3 specific substrate in Plk1-
depleted puromycin non-selected HeLa cells (Supplementary Fig. 2, A-B), virus-
infected cells were observed from 0 h to 24 h after release (from 24 h to 48 h after 
infection). In order to determine the sequence of events following Plk1 depletion, the 
formation of γ-H2A.X foci and the activation of caspase-3 were measured (Fig. 1). The 
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level of Plk1 depletion was checked by immunoblot (Fig. 1A), and the cell cycle was 
followed with FACS analysis (Fig. 1B). As expected, cycling was slower in Plk1-
depleted cells than in control cells, and the population of subgenomic DNA, an 
indication of apoptosis, increased beginning at 24 h in Plk1-depleted cells (Fig. 1B). 
Caspase-3 activity was elevated 2-fold in Plk1-depleted cells relative to control cells at 
24 h (Supplementary Fig. 2B). In addition, γ-H2A.X foci-positive cells were visible at 0 
h (24 h after infection) in Plk1-depleted cells and the population of γ-H2A.X foci-
positive cells increased with time as compared with control virus-infected cells (Fig. 1, 
C and D). In contrast, cleaved caspase-3 was not detected until 12 h (Fig. 1, C and E). 
To support the association of Plk1 depletion and H2A.X phosphorylation, Plk1-depleted 
mitotic cells were stained with anti-p-histone H2A.X (Ser139) antibody at 10 h after 
release from the double thymidine block. As shown in Supplementary Fig. 3, H2A.X 
protein was phosphorylated in Plk1-depleted cells. 
 
The involvement of p53 in DNA damage and apoptosis by Plk1 depletion and the 
dependency on p73 in p53-deficient cells.  
To analyze the involvement of p53 in DNA damage and cell death following Plk1 
depletion, these experiments were repeated with U2OS cells (p53 wild type), Saos2 
(p53 null), and H1299 (p53 null) cells. As was the case with HeLa, γ-H2A.X foci-
positive cells were already visible at the end of the double thymidine block in Plk1-
depleted cells and the percentage of γ-H2A.X foci-positive cells increased with time 
compared with control virus-infected cells (Fig. 2A). Activated caspase-3 was detected 
between 12 h to 24 h after release, later than the formation of γ-H2A.X foci and this 
pattern was p53-independent (Fig. 2, A and B). In H1299 cells, apoptosis was severe, as 
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shown subgenomic DNA content (Fig. 2C). 
In order to obtain evidence of checkpoint activation in p53-null cells, we analyzed the 
level of phosphorylated Chk2 on T68 in Plk1-depleted H1299 p53-null cells. As shown 
in Figure 2D, Chk2 was phosphorylated by the end of the second thymidine block and 
the level of p-Chk2 increased with time. These data are consistent with the timing of γ-
H2A.X foci formation (Fig. 1C, 1E and 2A). In contrast, Chk1 phosphorylation was not 
detected until 24 h after release from the double thymidine block in Plk1-depleted cells 
(Fig. 2D). Chk2 drives E2F1 activation and p73 expression, which in turn induce 
expression of pro-apoptotic proteins such as Bax and Apaf-1 in p53-independent 
apoptotic progression (27). The protein levels of E2F-1 and p73 were analyzed by 
western blot (Fig. 2D). As expected, p53 protein was not detected (unpublished data). 
The protein levels of E2F-1, a target of Chk2, and of p73 were elevated by the end of 
second thymidine block in Plk1-depleted H1299 cells.  
We examined the influence of p73 on apoptosis in Plk1-depleted H1299 cells (Fig. 2, E-
G). Twenty hours after release from the double thymidine block, depletion of p73 
reduced the level of subgenomic DNA induced by Plk1 depletion in H1299 cells as 
determined by FACS analysis (Fig. 2, E-F). In addition, twelve hours after release from 
the double thymidine block, the transfection of p73 siRNA reduced the expression of 
Bax in control cells, while the level of Bax showed only a modest increase in Plk1-
depleted cells (Fig. 2G). These data suggest that Plk1 depletion resulted in DNA 
damage at the G1/S transition, and activated the Chk2-E2F1-p73 checkpoint-signaling 
pathway. This activation may contribute to apoptosis through the expression of Bax 
mediated by p73 in p53-null cells. 
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DNA damage is induced in early S phase in Plk1-depleted cancer cells.  
As shown in Figure 2D, checkpoint signaling was activated at the G1/S transition in 
Plk1-depleted p53-null cells. To further confirm that DNA damage occurs in early S 
phase, a comet assay was carried out in Plk1-depleted HeLa cells that were 
synchronized by the double thymidine block and treated with hydroxyurea to arrest 
them in G1/early S phase. At 0 h after release from the second thymidine block, 14% of 
Plk1-depleted cells displayed a comet-like shape, which is an independent measure of 
DNA damage (21) (Fig. 3, A and B). This percentage increased up to 27% at 6 h when 
the cells were in G2/M phase. When cells were treated with hydroxyurea after the 
double thymidine block, the population of comet-tailing cells was 13% in Plk1-depleted 
cells (versus 5% in control cells) (Fig. 3B). FACS analysis was performed to confirm 
the cell cycle phase (Fig. 3C).  
We also assessed the percentage of γ-H2A.X foci-positive cells over time after release 
from the double thymidine block (Fig. 3D). Consistently, upon Plk1 depletion the 
percentage of γ-H2A.X foci-positive cells was elevated at 0-2 h in early S phase as 
judging FACS analysis, and at 6 h after release increased 3-fold compared to control 
cells. These results show that Plk1 depletion does induce DNA damage in early S phase, 
however the effect in G2/M is greater. 
 
Plk1 depletion disrupts the binding of Mcm proteins to chromatin.  
The above data indicate that Plk1 depletion induced DNA damage not only in G2/M but 
also in S phase. It is well known that Plk1 plays multiple and critical roles in mitosis but 
only recently have some reports suggested that Plk1 may have a function in S phase (32, 
35). We found DNA synthesis in Plk1-depleted HeLa cells was about one-half that in 
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control cells at 2 h after release as determined by BrdU incorporation for 30 min (Fig. 4, 
A and B). However, incorporation of BrdU for 60 min was not markedly reduced in 
Plk1-depleted cells compared to that of control cells. These data indicate that DNA 
synthesis was not completed blocked but slowly occurred at the early time after Plk1 
depletion.  
To address how Plk1 depletion may influence DNA synthesis, chromatin-binding assays 
were performed to observe pre-RC formation. At 2 h after release from the double 
thymidine block, cells were collected and fractionated into soluble and chromatin 
fractions. As shown in Figure 4C, the level of chromatin-bound Mcm7 was decreased 
and conversely, the level of soluble Mcm7 was increased in Plk1-depleted cells as 
compared with in control. As was the case with Mcm7, the level of chromatin-bound 
Mcm3 was also decreased in Plk1-depleted cells compared with control (Fig. 4C). To 
determine whether Plk1 kinase influences loading Mcm proteins on pre-RC, a 
chromatin binding assay was performed. pEGFP-mouse-Plk1 wild type (WT) or kinase 
defective Plk1 (K82M) was transfected in Plk1-depleted or control HeLa cells. Two 
hours after release from the double thymidine block, the level of chromatin-bound 
Mcm7 decreased when Plk1-KM was expressed in control and Plk1-depleted cells (Fig. 
4D). In Plk1-depleted cells, the level of chromatin-bound Mcm7 increased when Plk1-
WT was expressed compared to GFP-mock transfected cells. The reduction of 
chromatin-bound Mcm7 caused by Plk1 depletion was restored by expression of Plk1-
WT. These data indicate that Plk1 plays a role in the loading of Mcm proteins on Pre-
RC.  
The activity of ATM, a DNA damage-sensing kinase, was significantly activated within 
2 h after release from the double thymidine block in Plk1-depleted cells (Fig. 4E, left 
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panel). ATR which is activated as a result of stalled DNA replication was modestly 
activated at this point (Fig. 4E, right panel). These data indicate that Plk1 depletion 
disrupted Mcm proteins binding to chromatin in early S phase, presumably affecting 
DNA synthesis. Thus, Plk1 depletion may result in DNA damage caused by disruption 
of the pre-replication complex.  
 
Disruption of the pre-RC by Plk1 depletion is associated with the accumulation of 
Emi1 and geminin.  
To investigate the mechanism that leads to disruption of pre-RC, the protein level of 
geminin, an inhibitor of Cdt1 in pre-RC and a target of anaphase promoting 
complex/cyclosome (APC/C), was determined by western blot. During mitosis, Plk1 
phosphorylates Emi1, an inhibitor of APC/C. Thus Emi1 protein is degraded mediated 
by phosphorylation and APC/C is no longer inhibited (10, 22). Plk1 depletion may 
stabilize Emi1 and consequently, the degradation of geminin would be reduced. As 
expected, the levels of geminin and Emi1 were greater in Plk1-depleted cells than in 
control cells at the end of the second thymidine block (Fig. 5A). At the same time, the 
kinase ATM, a DNA damage-sensing kinase, was phosphorylated on S1981 in Plk1-
depleted cells. In addition, Chk2, a DNA damage signaling kinase, was phosphorylated 
on T68 in Plk1-depleted cells although the protein level of Chk2 was not altered (Fig. 
5A). We determined whether Emi1 protein level is directly affected by the protein level 
and kinase activity of Plk1. pEGFP-mouse-Plk1-WT or kinase defective mutant was 
transfected into the Plk1-depleted or control HeLa cells, and the protein level of Emi1 
was observed by immunohistochemistry at 2 h after release from the double thymidine 
block (Fig. 5B). The intensity of the immunofluorescent signal of Emi1 increased in 
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Plk1-depleted cells compared with that of control cells (Fig. 5B). In GFP expressed 
cells, the level of Emi1 was not altered between transfected and nontransfected cells in 
both control- or Plk1-depleted cells. However, in GFP-tagged Plk1-WT expressed cells 
the level of Emi1 decreased compared with that of the non-transfected cells. While, the 
level of Emi1 significantly increased in GFP-Plk1-kinase defective mutant (KM)-
expressed cells compared with that of non-transfected cells cells in both control- or 
Plk1-depleted cells.  
In Plk1-depleted cells, the increased level of Emi1 by Plk1 depletion was recovered by 
expression of GFP-Plk1-WT. However, the expression of Plk1 kinase defective mutant 
significantly increased the level of Emi1 (Fig. 5B). In addition, the levels of Emi1 and 
geminin were checked by western blot (Supplementary Fig.4S). In control virus-
infected cells, the level of Emi1 decreased when Plk1-wt was expressed (Supplementary 
Fig. 4S), whereas levels of Emi1 and geminin increased in GFP-Plk1-KM expressing 
cells. In Plk1-depleted cells, the levels of Emi1 and geminin slightly decreased when 
pEGFP-Plk1-wt was expressed whereas, the levels increased in cells expressing Plk1-
KM (Supplementary Fig. 4S). These results suggest that Plk1 depletion causes the 
increase in the level of Emi1 and geminin as a consequence of the attenuation of their 
degradation, and that the increased level of geminin could inhibit pre-RC formation in 
Plk1-depleted cells.  
To observe the correlation between the level of geminin and pre-RC disruption, 
chromatin binding assay and immunoprecipiation were performed. At 2h after release 
from the double thymidine block, the level of chromatin-bound Cdt1 was decreased in 
Plk1-depleted cells compared to control (Fig. 5C). The levels of soluble Cdt1 and 
geminin were increased and soluble Cdt1 was phosphorylated in Plk1-depleted cells. 
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Using this soluble fraction, geminin was immunoprecipitated and an immunoblot was 
performed with anti-Cdt1 antibody (Fig. 5D). As expected, soluble geminin bound to 
Cdt1 in Plk1-depleted cells. These data implied that stabilized soluble geminin binds 
Cdt1, reduced the chromation binding of Cdt1 to the pre-RC, and consequently 
disrupted pre-RC formation upon Plk1 depletion. 
 
DNA damage occurred in G1/S and DNA synthesis was reduced in Plk1-depleted 
T98G cells. 
T98G cells can efficiently be synchronized in G1 phase by serum starvation, which 
provides an alternative to the double thymidine approach to evaluate the influence of 
Plk1 depletion in G1/S phase. At 2 days after serum deprivation, the cells were infected 
with Plk1-targeting lentivirus for 1 day. Then the cells were stimulated by the addition 
of serum. The DNA damage response was checked by ATM activity. Consistent with 
the previous data, ATM kinase was activated at 12 h after serum release during early S 
phase in Plk1-depleted T98G cells (Fig. 6, A and C). The percentage of γ-H2A.X foci-
positive cells was 7.8% at 12 h and then gradually increased up to 10% at 20 h after 
serum addition in Plk1-depleted T98G cells (Fig. 6, B and C). Moreover, the level of 
ATM phosphorylated on S1981 was much greater in Plk1-depleted cells than that of 
control cells at 16 h after serum stimulation as determined by western blot (Fig. 6F). 
Thus, ATM, which senses DNA damage was activated in G1/S when Plk1 was depleted 
in T98G cells. In addition, the G1/S peak was sharper in Plk1-depleted cells than in 
control cells at 12 h to 16 h (Fig. 6C). This result indicates that the cell cycling is much 
slower in Plk1-depleted cells than in control cells in early S phase. These results suggest 
that Plk1 depletion initially induced DNA damage in early S phase and this increased in 
 13 
G2/M phase. The rate of DNA synthesis decreased to about 2% in Plk1-depleted T98G 
cells as compared with 70% in control cells at 16 h after release from serum starvation 
(Fig. 6, D and E). This inhibition was much more severe than that in HeLa cells 
synchronized by the double thymidine block (Fig. 6, D and E; Fig. 4, A and B).  
We determined the levels of Emi1 and geminin in serum-starved T98G cells, and found 
the levels of Emi1 and geminin are greater in Plk1-depleted cells than those in control 
cells at 16 h after release from serum starvation (Fig. 6F). Thus, the level of Emi1 and 
geminin increased after Plk1 depletion in the serum starved T98G cells. In order to 
extend the observation that Emi1 accumulated in the Plk1-depleted HeLa cells, the 
Plk1-depleted T98G cells were synchronized with double thymidine block. The DNA-
damage response was checked by phosphorylation of Chk2 kinase on T68. In consistent 
with the previous data, Chk2 was phosphorylated at 2 h after serum release during early 
S phase in Plk1-depleted T98G cells (Fig. 6G). At the same time, the level of Emi1 was 
greater in Plk1-depleted T98G cells than in control cells (Fig. 6G). Thus, Plk1 depletion 
did lead to increased levels of Emi1 and phosphorylated Chk2 in early S phase. These 
results show that Plk1 depletion caused the accumulation of Emi1 and induced the 
activation of Chk2 in T98G cells independent with synchronization method. 
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DISCUSSION 
 
In this manuscript we describe studies on the sequence of events that lead to cell death 
in cancer cells depleted of Plk1. Upon depletion of Plk1 DNA damage becomes evident, 
as detected by phosphorylation of H2A.X. We specifically examined whether activation 
of enzymes commonly associated with apoptosis precedes or follows DNA damage. We 
found that DNA damage is an early event and that it leads to activation of ATM, 
phosphorylation of Chk2 and activation of caspases. Depletion of Plk1 results in the 
accumulation of Emi1, an APC/C inhibitor, which prevents the destruction of geminin, 
an inhibitor of pre-replicative complex formation (Fig. 7). Although DNA synthesis is 
only moderately delayed in Plk1-depleted cells, pre-replication complex formation is 
disrupted, as shown by underloading of Mcm proteins (See Fig. 4). Mammalian pre-RC 
assembly takes place during telophase and early G1 phase, mediated by post-
translational modifications of pre-existing proteins (23). Plk1 interacts with pre-RC 
components, and Mcm2-7 and Orc2 proteins colocalize in the centrosome where Plk1 is 
located at the end of mitosis (32, 35). Based on these reports and our data, Plk1 may 
phosphorylate pre-RC components during pre-replicative complex formation at 
replication origins and it may be required for pre-RC assembly. If so, Plk1 depletion 
itself could lead to the disassembly of pre-RC during the telophase to G1 transition. A 
recent report shows that Plk1 interacts with and phosphorylates the DNA pre-RC 
regulatory protein histone acetyltransferase binding to Orc1 (Hbo1) (39). Hbo1 
phosphorylation may be required for pre-RC formation, and thus Plk1 may regulate 
replication licensing by this pathway.  
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A recent report indicates that in Xenopus egg extracts Plx1 is required for DNA 
replication in the presence of stalled replication forks induced by treatment with 
aphidicolin or etoposide (34). However, that study is fundamentally different from the 
work presented here, as Plx1 was immunodepleted, which has the potential to remove 
other proteins that interact with it. Addition of recombinant protein produced in insect 
cells does not entirely resolve this issue as it, too, may contain Plx1- associated proteins 
derived from the insect cells. It could be argued that the double thymidine block 
employed in our experiments results in a stress condition equivalent to that caused by 
the inhibitors used in the Xenopus egg extracts. However, we also observe evidence of 
DNA damage, as shown by H2A.X phosphorylation and ATM activation, in cells 
synchronized by serum starvation as they enter S phase at 12 hours after serum 
stimulation (see Fig. 6). Presumably such synchronized cells represent a normal 
unperturbed population. 
Recent reports show that ATM is activated in response to replication stress (24, 31, 40). 
ATM is activated during DNA replication stress induced by aphidicolin resulting in 
fragile site generation, and DNA fragmentation. These results provide evidence for 
double-stranded DNA breaks and recruitment of phosphorylated ATM to nuclear foci 
(24). Other reports indicate that replication stress inducers, hydroxyurea and aphidicolin, 
also activate the ATM-dependent signaling pathway mediated by NF-kB activation. 
ATM is the essential DNA damage signal transducer for NF-kB activation in response 
to replication stress (40). Plk1 depletion led to early activation of Chk2 and ATM in 
G1/S whereas Chk1 activation was undetectable or delayed. These data indicate that 
Plk1 depletion induced double stranded DNA breaks rather than single-stranded DNA 
breaks. Plk1 depletion appears to cause pre-replication complex disruption and activate 
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ATM signaling pathway. 
p53, a key regulator of cellular stress, is activated by DNA damage-sensing kinases and 
checkpoint kinases. We evaluated DNA damage and apoptosis after Plk1 depletion in 
cancer cells expressing different levels of p53. DNA damage preceded apoptosis and 
was p53-independent, but the degree of DNA damage and the time of caspase-3 
activation were delayed in p53-wt cells as compared to p53-null cancer cells. H1299 
p53-null cells displayed more severe accelerated DNA damage and apoptosis than 
U2OS and HeLa cells. In p53-null cells, DNA damage leading to apoptosis may be 
mediated by p73; p53 requires p63 and p73 for triggering apoptosis in response to DNA 
damage (5). However, p73 is pro-apoptotic in the absence of p53 as a result of NOXA 
transcription and BAX translocation (16, 20). p73 knockdown prevents the expression 
of NOXA as well as PARP cleavage in p53 deficient HCT 116 cells treated with Nutlin, 
an apoptotic inducer (16). It has been reported that Chk1/Chk2-driven E2F1 activation 
and p73 up-regulation in turn lead to expression of pro-apoptotic proteins such as Puma 
and Bax in p53-independent apoptotic progression (11, 20, 30, 36). Another report 
indicates that Plk1 phosphorylates p73 protein directly, inhibits its proapoptotic activity 
and reduces its stability (13). Thus, Plk1 depletion may increase the level of p73 directly 
or through E2F1. In support of this interpretation, our experiments reveal that the level 
of p73 increased in Plk1-depleted H1299 cells and the depletion of p73 reduced the 
expression of Bax.  
We have demonstrated that Plk1 depletion induces DNA instability, which may be 
mediated by the accumulation of Emi1, an inhibitor of APC/C, and geminin, an 
inhibitor of Pre-RC formation. There is evidence supporting the correlation between 
Plk1, Emi1, APC/C, and geminin. First, depletion of Cdh1, an APC activator during late 
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mitosis and early G1, induces premature and prolonged S phase, cytokinesis defects, 
and multipolar mitosis, similar to the Plk1-depletion phenotype (4). These authors 
suggest that depletion of Cdh1 leads to the stabilization of target proteins of APC/C and 
thus may initiate aberrant DNA replication and genomic instability. Second, 
overexpression of non-degradable Emi1, an inhibitor of APC, also results in similar 
cellular morphology that correlates with the level of Emi1 and the extent of cell death 
(19). Third, the expression of non-degradable geminin mutated in the destruction box 
reduces the quantity of Mcm2 bound to chromatin, blocks cell cycle with an early S 
phase arrest, leads to the activation of checkpoint machinery, and eventually triggers 
apoptosis in U2OS cells (28). They also show that in primary fibroblasts IMR90, the 
expression of non-degradable geminin did not induce apoptosis. These phenotypes are 
very similar to those observed in Plk1-depleted cancer cells compared to normal cells. 
Thus, the absence of APC/C activation as the result of Emi1 accumulation may 
contribute to DNA instability and cell death in Plk1-depleted cells. 
In summary, Plk1 depletion leads to the accumulation of Emi1 and geminin protein, 
which appears to contribute to disrupted DNA pre-RC formation, reduced DNA 
synthesis and subsequent DNA damage before cells undergo severe mitotic catastrophe 
or apoptosis. Our data suggest that Plk1 is required for accurate cell cycle progression 
not only in mitosis but also during DNA synthesis. 
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MATERIALS AND METHODS 
 
Cell culture, Synchronization, and Treatments 
HeLa, U2OS, Saos2, T98G and 293T cells were grown in Dulbeco’s modified Eagle’s 
medium (Invitrogen; Carlsbad, CA, USA) and H1299 cells were grown in RPMI 1640 
medium (ATCC; Manassas, VA, USA) supplemented with 10% fetal bovine serum in 
the presence of antibiotics in a humidified 5% CO2 incubator at 37°C. HeLa, U2OS, 
Saos2, H1299, T98G cells were synchronized with 2.5 mM thymidine (Sigma; St. Louis, 
MO, USA) for 16 h, released with fresh medium and also infected with lentivirus-
expressing RNAi targeting Plk1 at nucleotide 1424 (P), control lentivirus carrying the 
hairpin-pLKO-puro.1 vector (C), or off-site lentivirus carrying mutant sequence of Plk1 
(M). After 8 h, cells were again treated with 2.5 mM thymidine for 16 h, released with 
fresh medium from the double thymidine block and then samples were prepared at 
various times. To block cells in G1/early S, cells were treated with 4 mM hydroxyurea 
(Sigma; St. Louis, MO, USA) for 6 h after release from double thymidine block.  
 
Lentivirus-based RNAi Plasmid Preparation, Virus Production, and Infection. 
The lentivirus-based RNAi transfer plasmids targeting human Plk1 at 1424-1444 
(AGATCACCCTCCTTAAATATT) (pLKO-Puro.1-Plk1), Plk1 mutant at 1424-1444 
(AGAGCACCCTACTTAGATATT) (pLKO-Puro.1-Plk1-mt) for off-site targeting, or 
control plasmid (pLKO-Puro.1) were prepared and control lentivirus (C), Plk1 targeting 
lentivirus (P), and off-site lentivirus (M) were generated as described previously (17). 
Infections were carried out in the presence of 10 µg/ml polybrene and 10 mM HEPES. 
Selection with puromycin was not carried out because the infection efficiency was high 
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and puromycin may have unknown secondary effects to DNA damage. Transfections 
were performed with pEGFP, pEGFP-mouse-Plk1 wild type (WT) or kinase defective 
mutant (K82M) (12) and Polyfect (Qiagen; Valencia, CA, USA) into the Plk1-depleted 
or control cells according to the manufacturer’s protocols when cells were released from 
the first thymidine block. 
 
siRNA transfection 
For depletion of human p73, H1299 cells were transfected with non-targeting siRNA 
control (Cat. No. D-001810-01-05; Dharmacon) and human p73 siRNA (target 
sequence :GAGACGAGGACACGUACUA) from Dharmacon (Lafayette, CO, USA) 
using Oligofectamin (Invitorgen; Carlsbad, CA, USA) according to the manufacturer’s 
protocols. At 32 h after transfection, cells were synchronized with 2.5 mM thymidine 
for 16 h, released with fresh medium and infected with lentivirus-expressing RNAi 
targeting Plk1 (P), or control lentivirus carrying the hairpin-pLKO-puro.1 vector (C). 
After 8 h, cells were again treated with 2.5 mM thymidine for 16 h, released with fresh 
medium from the double thymidine block and assayed. 
 
Immunofluorescence  
For immunofluorescence, cells grown on coverslips were fixed with 4% 
paraformaldehyde and permeabilized with methanol. Cells were washed three times 
with 0.1% Triton X-100 in PBS, incubated overnight at 4°C in 0.1% Triton X-100-PBS 
containing 3% BSA for blocking, and then incubated with cleaved caspase-3 (D175) 
polyclonal and p-histone H2A.X (Ser139) monoclonal antibodies from Cell Signaling 
(Danvers, MA, USA). Cells were washed three times with 0.1% TritonX-100-PBS and 
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then incubated with CyTM3-conjugated anti-rabbit secondary antibodies (Jackson 
Immuno Research Laboratories; West Grove, PA, USA) or FITC-conjugated anti-
mouse secondary antibodies (Invitrogen; Carlsbad, CA, USA) and 4ʹ′, 6- diamidine-2-
phenylindole (DAPI) (Sigma; St. Louis, MO, USA) for staining nuclear DNA. Image 
were collected and analyzed by the Z series of Applied Precision Deconvolution 
Microscope and Deltavision software. 
 
Fluorescence-activated cell sorting (FACS) analysis  
For the determination of the population of subgenomic DNA as an apoptotic index, cells 
were collected by trypsinization and fixed in 75% ethanol, stained with 500 µl of 50 µg 
/ml propidium iodide solution, and subjected to FACS analysis. Cells were sorted and 
analyzed by the Becton Dickinson (Franklin Lakes, NJ, USA) FACScan machine and 
CellQuest sofeware. 
 
Comet assay  
CometAssayTM kit was from Trevigen (Gaithersburg, MD, USA) and the experiments 
were performed according to the manufacturer’s protocols.  
 
Fluorometric caspase-3 activity assay 
Fifty µg of whole cell lysates was incubated with 200 nM Ac-DEVD-AMC (BD 
Biosciences; Franklin Lakes, NJ, USA) in reaction buffer [20 mM Hepes (pH 7.4), 2 
mM DTT, 10% glycerol] at 37 °C for 1 h. The reaction was monitored by fluorescence 
emission at 465 nm (excitation at 360 nm) and measured with a Spectramax Gemini XS 
Fluorescent Plate Reader. 
 21 
 
5-Bromo-2ʹ′-deoxy-uridine (BrdU) labeling assay  
5-Bromo-2ʹ′-deoxy-uridine (BrdU)-labeling and -detection kit was from Roche Applied 
Science (Indianapolis, IN, USA). The assay was carried out according to the 
manufacturer’s protocols.  
 
Chromatin-Binding Assay  
Chromatin was fractionated with Triton X-100. The soluble fraction of cells was 
prepared by lysis in 200 µl CSK buffer [10 mM PIPES (pH 6.8), 100 mM NaCl, 300 
mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 50 mM NaF, 0.1 
mM sodium vanadate, 0.5% Triton X-100 and protease inhibitor cocktail (Roche; 
Indianapolis, IN, USA)] for 5 min on ice. Cell lysates were centrifuged at 7,500 rpm for 
5 min at 4°C and the supernatants were collected. The chromatin pellet was washed 
again with CSK buffer and centrifuged at 7,500 rpm for 5 min at 4°C. For nuclease 
digestions, chromatin pellets were resupsended in lysis buffer containing 30 units of 
micrococcal nuclease (Roche; Indianapolis, IN, USA) and 1 mM CaCl2 and then 
incubated at 37°C for 10 min followed by chilling on ice and centrifugation. After 
adjusting the protein concentration, proteins were resolved by SDS-PAGE and analyzed 
by western blot with anti-Mcm7 (Santa Cruz; Santa Cruz, CA, USA), anti-Mcm3 
(BioLgend, San Diego, CA, USA), anti-nucleophosmin (Zymed; Carlsbad, CA, USA), 
anti-Plk1 (Upstate; Billerica, MA, USA), anti-Erk2 (Santa Cruz; Santa Cruz, CA, USA) 
anti-geminin, and anti-Cdt1 (Bethyl Lab, Montgomery, TX, USA) antibodies. For 
immunoprecipitation assays, geminin was immunoprecipitated from soluble fraction 
with anti-geminin antibody (Bethyl Lab, Montgomery, TX, USA) for 4 h at 4°C with 
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end-over-end mixing, followed by incubation with protein A agarose (Upstate; Billerica, 
MA, USA) for 2 h at 4°C. Immunoprecipitates were subjected to immunoblot with anti-
geminin and anti-Cdt1 antibodies. 
 
Kinase assay 
ATM was immunoprecipitated from cell lysates with an anti-ATM polyclonal antibody 
(Santa Cruz; CA, USA) for 4 h at 4°C with end-over-end mixing, followed by 
incubation with protein A agarose (Upstate; Billerica, MA, USA) for 2 h at 4°C. 
Immunoprecipitates were separated from supernatants by centrifugation and washed 
with lysis buffer. The reaction for ATM activity was performed as described (41). The 
samples were suspended in SDS loading buffer, resolved by SDS-PAGE and detected 
by autoradiography. 
 
Immunoblot analysis 
Cells were collected and extracted in lysis buffer [0.5% Triton X-100, 20 mM Tris, pH 
7.5, 2 mM MgCl2, 1 mM dithiothreitol (DTT), 1 mM EGTA, 50 mM β-
glycerophosphate, 25 mM NaF, 1 mM Na vanadate, 100 µg/ml PMSF, and protease 
inhibitor cocktail (Roche; Indianapolis, IN, USA)]. After adjusting the protein 
concentration, proteins were resolved by SDS-PAGE and analyzed by western blot 
analysis with the appropriate antibodies. Anti-Erk2, anti-Chk2, and anti-Bax polyclonal 
antibodies and anti-cyclin B1 and anti-E2F1 monoclonal antibodies were from Santa 
Cruz (Santa Cruz, CA, USA). Anti-Plk1 monoclonal from Upstate (Billerica, MA, 
USA), anti-p-Chk2 (T68), and anti-p-Chk1 (S345) polyclonal from Cell Signaling 
(Danvers, MA, USA), anti-p53 monoclonal from Oncogene (San Diego, CA, USA), 
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anti-p-ATM (S1981) monoclonal from Calbiochem (Gibbstown, NJ, USA), anti-
geminin polyclonal from Bethyl Lab (Montgomery, TX, USA), anti-p73 and anti-Emi1 
polyclonal antibodies from Zymed (Carlsbad, CA, USA) were used. Immune complexes 
were revealed using Amersham ECLTM western blotting detection reagents (GE 
Healthcare; Piscataway, NJ, USA).  
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Figure Legends 
 
Figure 1. The formation of γ-H2A.X foci precedes the activation of caspase-3 in 
Plk1-depleted HeLa cells. HeLa cells were synchronized with double thymidine block 
and infected with either lentivirus expressing RNAi targeting Plk1 (P) or control (C) as 
described in Materials and methods. Note: Zero time of release is 24 hrs after infection. 
(A) Whole cell lysates were subjected to immunoblot analysis with anti-Plk1 and anti-
Erk2 antibodies. (B) FACS analysis of cell cycle progression. (C) HeLa cells grown on 
coverslips were fixed with 4% paraformaldehyde and examined for phosphorylated 
H2A.X (Green) or cleaved caspase-3 (Red). Nuclear DNA was stained with DAPI. The 
scale bar indicates 10 µm. (D-E) The γ-H2A.X- and cleaved caspase-3-positive cells 
were counted and quantified.  
 
Figure 2. The involvement of p53 and p73 in DNA damage induced by Plk1 
depletion. Cells were synchronized with double thymidine block and infected with 
lentivirus-expressing RNAi targeting Plk1 or control. (A-B) The γ-H2A.X- or cleaved 
caspase-3-positive cells were counted and quantified. (C) FACS analysis of cell cycle 
progression in Plk1-depleted H1299 cells. (D) Extracts of H1299 cells were subjected to 
immunoblot analysis with anti-p-Chk2 (T68), anti-E2F1, anti-p73, anti-p-Chk1 (S345), 
anti-Plk1 and anti-Erk2 antibodies. (E-G) H1299 cells were transfected with human p73 
siRNA and infected with human Plk1 targeting lentivirus during the double thymidine 
block as described in Materials and methods. (E-F) At 12 h and 24 h after release from 
the double thymdine block, cells were prepared and FACS analysis was performed. The 
subgenomic DNA was quantified. (G) At 12 h after release from the double thymidine 
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block, extracts were subjected to immunoblot analysis with anti-p73, anti-Plk1, anti-Bax, 
and anti-Erk2 antibodies. 
 
Figure 3. DNA damage occurs in G1/early S phase in HeLa cells. HeLa cells were 
synchronized with double thymidine block and infected with lentivirus-based RNAi 
targeting Plk1 (P) or with control (C) virus. (A-B) Cells were released with fresh 
medium in the presence or absence of hydroxyurea. Cells with DNA damage are 
visualized by the comet assay, and quantified. The scale bar indicates 50 µm. (C) FACS 
analysis of the cells shown in (A) and (B). (D) The γ-H2A.X-positive cells were 
counted and quantified at the indicated times. 
 
Figure 4. Plk1 depletion inhibits DNA synthesis and disrupts the binding of Mcm 
proteins to chromatin in early S phase. HeLa cells were synchronized and infected as 
described in Materials and methods. (A-B) At 1 h or 1 h 30 min after release, 5’-bromo-
2’-deoxy-uridine (BrdU) was added to the cells, and after 60 min or 30 min, the cells 
were fixed and labeled with anti-BrdU antibody (Green). Nuclear DNA was stained 
with DAPI. The scale bar indicates 50 µm. The 5’-bromo-2’-deoxy-uridine (BrdU)-
positive cells were counted and quantified. (C) At 2 h after release, cells were 
fractionated into soluble and chromatin fractions as described in Materials and methods, 
and subjected to immunoblot with anti-Mcm7, anti-Mcm3, anti-nucleophosmin, anti-
Plk1, and anti-Erk2 antibodies. (D) HeLa cells were infected with Plk1-targeting 
lentivirus or control virus. After 8 h, cells were treated with thymidine for 16 h and then 
transfected with pEGFP, pEGFP-Plk1-wild type (WT), or pEGFP-Plk1-K82M (KM). 
Murine Plk1 is resistant to human Plk1 RNAi. After 8 h, the cells were again treated 
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with thymidine for 16 h and then released with fresh medium. At 2 h after release, cells 
were fractionated into soluble and chromatin fractions and subjected to immunoblot 
with anti-Mcm7, anti-nucleophosmin, anti-Plk1, and anti-Erk2 antibodies. (E) At 2 h 
after release, extracts were subjected to ATM or ATR assay using anti-ATM antibody 
or anti-ATR antibody, respectively. The kinase activity was measured with PHAS-1 as a 
substrate. PHAS-1 was visualized by staining with coomassie brilliant blue. 
 
Figure 5. Plk1 depletion results in a high level of Emi 1 and geminin. (A) HeLa cells 
were synchronized and infected as described in Materials and methods. Whole cell 
lysates were subjected to immunoblot analysis with anti-Emi1, anti-geminin, anti-cyclin 
B1, anti-Plk1, anti-Erk2, anti-p-ATM (S1981), anti-p-Chk2 (T68), and anti-Chk2 
antibodies. (B) HeLa cells grown on coverslips were infected, synchronized and 
transfected as described in Figure 4D. At 2 h after release, cells were fixed with 4% 
paraformaldehyde and examined GFP (Green) or Emi1 (Red). Nuclear DNA was 
stained with DAPI. The scale bar indicates in 10 µm. (C) HeLa cells were synchronized 
and infected as described in Materials and methods. At 2 h after release, cells were 
fractionated into soluble and chromatin fractions, and subjected to immunoblot with 
anti-Cdt1, anti-geminin, anti-Plk1, and anti-Erk2 antibodies (D) The soluble extracts 
were subjected to immunoprecipitation assay using anti-geminin antibody and subjected 
to immunoblot with anti-Cdt1 and anti-geminin antibodies. 
 
Figure 6. DNA damage occurred in G1/ S transition and DNA synthesis was 
reduced in Plk1-depleted T98G cells. T98G cells were synchronized with serum 
starvation for 2 days and infected with lentivirus-based RNAi targeting Plk1 (P) or with 
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control virus (C) in serum free medium for 1 day. Cells were released with fresh 
medium containing 10% fetal bovine serum and then harvested at various times. (A) 
Extracts were subjected to ATM assay using anti-ATM antibody with PHAS-1 as 
substrate. PHAS-1 was visualized by staining with coomassie brilliant blue. Also 
immunoblot analysis was performed with anti-Plk1 and anti-Erk2 antibodies. (B) DNA 
damage was measured by immunohistochemistry using γ-H2A.X monoclonal antibody. 
The γ-H2A.X-positive cells were counted and quantified. (C) FACS analysis was 
performed. (D) At 16 h after release, 5’-bromo-2’-deoxy-uridine (BrdU) was added to 
the cells. After 30 min, cells were fixed and labeled by anti-BrdU antibody (Green). 
Nuclear DNA was stained by DAPI. The scale bar indicates 20 µm. (E) The 5’-bromo-
2’-deoxy-uridine (BrdU)-positive T98G cells were counted and quantified. (F) T98G 
cells were synchronized with serum starvation for 2 days and infected as described 
above. Whole cell lysates were subjected to immunoblot analysis using anti-p-ATM 
(S1981), anti-Emi1, anti-geminin, anti-Plk1, and anti-Erk2 antibodies. (G) T98G cells 
were synchronized with double thymidine block and infected with lentivirus as 
described above. Lysates were subjected to immunoblot analysis using anti-p-Chk2 
(T68), anti-Emi1, anti-Plk1, and anti-Erk2 antibodies. 
 
Figure 7. A model for the mechanism of DNA damage and cell death induced by 
Plk1 depletion. Under normal conditions, Plk1 phosphorylates Emi1, which results in 
degradation of Emi1 and activation of APC/C. Activated APC/C degrades the mitotic 
proteins such as cyclin B1 and geminin at the end of mitosis leading to exit from M 
phase. Upon Plk1 depletion, Emi1 is not phosphorylated by Plk1, which results in the 
accumulation of Emi1. The high level of Emi1 inhibits the APC/C activity, which leads 
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to a high level of geminin, an inhibitor of pre-replicative complex. Consequently, 
geminin disrupts the pre-RC and DNA-damage-sensing kinases are activated. 
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Supplementary Figure Legends 
 
Figure S1. Plk1 depletion induces apoptosis in HeLa cells. HeLa cells were infected 
with either lentivirus expressing RNAi targeting Plk1 (P), control (C), Plk1 mutant for 
off-site targeting (M) and selected with puromycin for 2 days. Cells were prepared at 3, 
4, or 5 days after infection. (A) FACS analysis of cell cycle progression. (B) Cell 
extracts were assayed for caspase-3 activity. Cell lysates treated with 50 µM etoposide 
for 20 h were used as a positive control for caspase-3 activity. RFU, relative 
fluorescence unit. (C) At 3 days after infection, HeLa cells grown on coverslips were 
fixed with 4% paraformaldehyde and examined for phosphorylated H2A.X (Green) or 
cleaved caspase-3 (Red). Nuclear DNA was stained with DAPI. The scale bar indicates 
20 µm. (D) The γ-H2A.X- and cleaved caspase-3-positive cells were counted and 
quantified.  
 
Figure S2. The activation of caspase-3 enzyme in Plk1-depleted and puromycine 
non-selected HeLa cells. Cells were synchronized with double thymidine block and 
infected with lentivirus expressing RNAi targeting Plk1 or control as described in 
Materials and methods. Note: Zero time of release is 24 hrs after infection. (A) The 
scheme of experiment. (B) Cell extracts were assayed for caspase-3 activity at the 
indicated times. RFU, relative fluorescence unit. 
 
Figure S3. The γ-H2A.X foci formed in Plk1-depleted HeLa cells. HeLa cells were 
synchronized and infected as described in Materials and methods. At 10h after release 
from double thymidine block, HeLa cells grown on coverslips were fixed with 4% 
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paraformaldehyde and examined phosphorylated H2A.X (Green) or Plk1 (Red). Nuclear 
DNA was stained with DAPI. The scale bar indicates 10 µm. 
 
Figure S4. Plk1 depletion results in a high level of Emi 1 and geminin. HeLa cells 
were infected with Plk1 targeting lentivirus or control virus. After 8 h, cells were treated 
with thymidine for 16 h and then transfected with pEGFP, pEGFP-Plk1-wild type (WT), 
or pEGFP-Plk1-K82M (KM). After 8 h, the cells were again treated with thymidine for 
16h and then released with fresh medium. At 2 h after release, cells were prepared and 
extracts were subjected to immunoblot analysis with anti-Emi1, anti-geminin, anti-Plk1, 
and anti-Erk2 antibodies.  
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